TEVA Pharmaceutical Industries (NYSE: TEVA) revenue
TEVA Pharmaceutical Industries reported revenue of $17,258m for fiscal 2025, 4.3% more than in fiscal 2024 ($16,544m). Since fiscal 2016 its revenue has fallen by 21.2%, an average decline of 2.6% a year.
TEVA Pharmaceutical Industries has grown its revenue for 3 years in a row, and its best year of the last 10 was fiscal 2016. The biggest drop was in fiscal 2018, −16.4%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $17,258m | +4.3% | $2,157m | 12.5% |
| 2024 | $16,544m | +4.4% | −$303.0m | −1.8% |
| 2023 | $15,846m | +6.2% | $433.0m | 2.7% |
| 2022 | $14,925m | −6.0% | −$2,197m | −14.7% |
| 2021 | $15,878m | −4.7% | $1,716m | 10.8% |
| 2020 | $16,659m | −1.4% | −$3,572m | −21.4% |
| 2019 | $16,887m | −7.6% | −$443.0m | −2.6% |
| 2018 | $18,271m | −16.4% | −$1,637m | −9.0% |
| 2017 | $21,853m | −0.2% | −$17,484m | −80.0% |
| 2016 | $21,903m | — | $2,154m | 9.8% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
TEVA Pharmaceutical Industries revenue compared with its sector
By revenue for its latest fiscal year, TEVA Pharmaceutical Industries ranks 30th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; TEVA Pharmaceutical Industries, 4.3%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 28th | Boston Scientific | $20,074m | 19.9% |
| 29th | Universal Health Services | $17,365m | 9.7% |
| 30th | TEVA Pharmaceutical Industries | $17,258m | 4.3% |
| 31st | IQVIA | $16,310m | 5.9% |
| 32nd | Regeneron Pharmaceuticals | $14,343m | 1.0% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of TEVA Pharmaceutical Industries
- How much revenue did TEVA Pharmaceutical Industries make in fiscal 2025?
- TEVA Pharmaceutical Industries reported revenue of $17,258m for fiscal 2025, compared with $16,544m in fiscal 2024.
- How much has the revenue of TEVA Pharmaceutical Industries fallen?
- Between fiscal 2016 and fiscal 2025 it went from $21,903m to $17,258m: 21.2% less, an average decline of 2.6% a year.
- What was the best year for revenue at TEVA Pharmaceutical Industries?
- Of its last 10 fiscal years, fiscal 2016, with $21,903m.
- Where does TEVA Pharmaceutical Industries rank in its sector by revenue?
- It ranks 30th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for TEVA Pharmaceutical Industries come from?
- From the annual report (Form 10-K) that TEVA Pharmaceutical Industries files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that TEVA Pharmaceutical Industries files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on TEVA Pharmaceutical Industries: the TEVA Pharmaceutical Industries page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.